|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||255.84 - 257.20|
|52 Week Range||222.50 - 277.31|
|PE Ratio (TTM)||21.97|
|Dividend & Yield||8.22 (3.19%)|
|1y Target Est||N/A|
Roche Holding AG (RHHBY) announced a label expansion of immunotherapy drug Tecentriq for the treatment of non-small cell lung cancer in Europe.
In June 2017, Roche (RHHBY) presented the results from the Phase 3 APHINITY trial.
In the first half of 2017, Roche’s (RHHBY) Herceptin reported revenues of CHF 3.5 billion, which is a 3.0% rise on a YoY (year-over-year) basis.